Skip to main content

Table 1 The changes in neurite composition under the influence of Aβ-induced degeneration and drug treatments

From: The neuritogenic and neuroprotective potential of senegenin against Aβ-induced neurotoxicity in PC 12 cells

Treatments & protein expression

Neurite quantity

Average length

Maximum length

NGF positive control w/ Gap-43

15.5 ± 2.38*

81.75 ± 15.33*

134.75 ± 22.91*

NGF positive control w/MAP2

10.5 ± 1.29*

68.75 ± 7.23*

139.0 ± 34.42*

Amyloid-β w/Gap-43

7.0 ± 1.83

41.0 ± 9.63

69.5 ± 21.25

NGF control w/MAP2

5.25 ± 0.957

48.0 ± 3.56

73.5 ± 8.18

Amyloid-β w/MAP2

4.0 ± 0.826

38.25 ± 11.44

49.25 ± 11.27

Senegenin 5 μg w/Gap-43

7.75 ± 1.71

46.5 ± 5.8

78.25 ± 17.35

Senegenin 5 μg w/MAP2

9.5 ± 2.38*

54.25 ± 7.04*

100.5 ± 24.15*

Senegenin 1 μg w/Gap-43

8.25 ± 1.71*

62.25 ± 8.06*

126.75 ± 36.86*

NGF treatment w/Gap-43

5.0 ± 3.56

45.0 ± 15.64

78.5 ± 36.74

  1. Cells were grown for 7 days in the presence of DM, followed by 4 days incubation with Aβ (25–35) peptide. The medium was then changed to include various concentrations of drugs for an additional 4 days to allow for neurite outgrowth. PC 12 cells were then fixed and labeled with primary antibodies
  2. *P < 0.01 vs. Amyloid-β treatment group
Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us